Maxim raised the firm’s price target on Gain Therapeutics (GANX) to $7 from $5 and keeps a Buy rating on the shares. The firm cites the company announcement of initial data from its Phase 1b study of GT-02287 in Parkinson’s disease patients, which was presented in a poster at the International Congress of Parkinson’s Disease and Movement Disorders. Safety was positive overall, and this pharmacokinetic / safety profile checks the right boxes, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GANX:
- Unusually active option classes on open October 6th
- Gain Therapeutics presents initial data from Phase 1b study of GT-02287
- Gain Therapeutics begins GT-02287 Phase 1b extension study in Parkinson’s
- Positive Buy Rating for Gain Therapeutics Driven by Promising Clinical Trial Developments and Strong Financial Outlook
- Promising Developments and Regulatory Milestones Bolster Buy Rating for Gain Therapeutics